Is Novo at $41 priced for the Wegovy pill or for the Wegovy price cut?

Nine points of guidance in nine months, and a share price down 19%

Novo Nordisk ($NVO) started 2026 by telling investors to expect a fall. The outlook of 3 February 2026 called for adjusted sales and operating profit to shrink by 5% to 13% at constant exchange rates, and the ADR lost 14.6% the next day. Since then the range has moved up three times: -4% to -12% on 6 May, -6% to 0% on 4 August and -2% to +2% on 4 November. The midpoint went from -9% to 0% in nine months.

The quarter to September 2026 forced the last raise. Adjusted sales came in at DKK 79.2 billion, up 4% at constant rates, and adjusted operating profit at DKK 31.7 billion, up 27%, against expectations of DKK 73.2 billion and DKK 28.4 billion. ADR EPS of $0.89 beat the $0.73 estimate by 21.9% - the fifth beat in a row. The stock still trades 18.7% lower in 2026 while the S&P 500 is up 10.3%.

The pill made DKK 5.4 billion while the US injection fell 13% - and Q4 is guided down

Wegovy pill, launched in the US on 5 January 2026, sold DKK 5,394 million in the quarter - DKK 4,178 million in the US and DKK 1,216 million abroad - against a consensus of DKK 4.62 billion, up 53% from the June quarter. That is 6.8% of group sales from a product that did not exist in 2025.

The pill is replacing as much as it adds. US injectable Wegovy fell 13% at constant rates; combined US Wegovy grew 21%. Adjusted gross margin reached 82.1% from 76.1% as the 2025 cost cuts landed. DKK 8.7 billion of non-cash write-downs - the failed heart drug ziltivekimab and surplus factory capacity - pushed reported net profit down 16% to DKK 16.7 billion.

Free cash flow guidance rose to DKK 60-70 billion from 45-55 billion and capital spending fell to around DKK 50 billion from 60 billion in 2025. But nine-month free cash flow is already DKK 83.8 billion, so the fourth quarter is guided to a cash outflow of DKK 14-24 billion as US rebates and taxes are paid. Sales also face a DKK 3 billion one-off US rebate benefit in the quarter to December 2025 as the base. The Street's fourth-quarter ADR EPS estimate is $0.68, 24% below the quarter just reported.

Why the model stops at $52.43: half the industry's P/E with twice its margin

The FPI fair value is $52.43, 26.7% above the $41.39 close on 9 November 2026. Half of that number comes from a discounted cash flow model. The inputs that lift a DCF for a company like this are all present: a net margin of 33.9% against an industry median of 14.4%, a return on invested capital of 32.8% against 11.1%, three-year revenue growth of 20.4%, and a capital spending curve the company expects to keep falling after 2026.

The peer leg points the same way. At 10.8x earnings the stock trades at half the industry median of 21.7x and well below the healthcare sector's 26.7x; EV/EBITDA of 7.1x compares with 13.4x. The market pays the multiple of a shrinking business for one now guiding flat. At the end of 2023 the same shares cost 37.5x earnings; at the end of 2025, 14.1x.

One correction: trailing earnings include a non-cash DKK 26.8 billion rebate-provision reversal booked in the quarter to March 2026. Nine-month adjusted EPS was DKK 18.60 against DKK 19.45 reported, so a clean P/E is nearer 11x - still half the industry. The 20% consensus leg, with a mean target of $44.67, pulls the blended number below what the other two legs would give alone.

Street vs model: a $47 median target, a $40 floor, and a $52.43 fair value

On 10 November 2026 the rating mix is 1 strong buy, 22 buy, 13 hold and 3 sell - a "buy" consensus on paper. The targets are tighter: low $40, median $47, mean $44.67, high $47 as of 12 October. The three targets issued in the last quarter averaged $42.33. The FPI fair value is 11.6% above the median target and 17.4% above the mean.

Targets fell while guidance rose. BMO Capital went from $57 on 26 January to $45 on 5 February, back to $47 on 6 August, then $40 on 12 October. Morgan Stanley set $40 with an Underweight rating on 11 September; Deutsche Bank moved from Hold to Sell on 27 August; Citigroup and HSBC stayed at hold.

The gap has a date on it. A 12-month target covers 2027, and from 1 January 2027 the US list price of Wegovy and Ozempic drops to $675 a month, about 50% and 35% below current levels, with the cash-flow effect landing in 2027. Semaglutide exclusivity is gone in Canada, and the Medicare Bridge programme that began on 1 July 2026 has no confirmed life beyond 2027. A DCF discounts cash over a far longer horizon, in which the 2030 ambitions set out on 21 September 2026 - revenue growth in line with peers, a broadly stable operating margin, more than five multi-blockbuster launches - weigh more than one year of price resets.

What moves $41: a $675 list price, a CagriSema decision, and the 200-day line at $43.59

For the price to close the gap to $52.43, 2027 has to look less like a cliff than the targets assume. US FDA decisions on CagriSema in obesity and on the 25 mg Ozempic pill are both due in the quarter to December 2026. The Wegovy pill is scheduled for more than 20 markets by mid-2027, pulled forward from end-2027. The 2027 outlook on 3 February 2027 is the single most important date: a midpoint above 0% would be the first guided growth since 2025.

For the price to slide toward the $40 targets, that outlook would need a negative midpoint, or US injectable Wegovy would have to fall faster than 13%.

Signals to watch:

• Fourth-quarter ADR EPS against the $0.68 estimate and revenue against $11.54 billion on 3 February 2027.
• Adjusted operating margin holding near the 40.1% of the September quarter or the 43.0% of nine months.
• Full-year free cash flow inside DKK 60-70 billion, which funds a 4.34% dividend yield after DKK 51.9 billion of dividends in nine months.
• Price against the 200-day average of $43.59 and the 50-day of $40.50.